Renin-angiotensin System activation in congenital hepatic fibrosis in the pck rat model of autosomal recessive polycystic kidney disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 50, Issue 6, 2010, Pages 639-644

  Goto, Miwa ^a   Hoxha, Nita ^a   Osman, Rania ^a   Wen, Jessica ^b   Wells, Rebecca G ^c   Dell, Katherine MacRae ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiotensin converting enzyme; Congenital hepatic fibrosis; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY POLYCYSTIC DISEASE; LIVER FIBROSIS; LIVER HISTOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION; LIVER; LIVER CIRRHOSIS; MALE; PEPTIDYL-DIPEPTIDASE A; POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 77953160860     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181cc80e4     Document Type: Article

References (22)

1. Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 2003;111:1072-80.
2. Kamath BM, Piccoli DA. Heritable disorders of the bile ducts. Gastroenterol Clin North Am 2003;32:857-75.
3. Dell KM, Avner ED. Autosomal recessive polycystic kidney disease. Gene Clinics: Clinical Genetic Information Resource [database online]. University of Washington, Seattle. http://www.geneclinics.org. Published July 2001. Accessed March 29, 2010.
4. Shneider BL, Magid MS. Liver disease in autosomal recessive polycystic kidney disease. Pediatr Transplant 2005;9:634-9.
5. Davis ID, Ho M, Hupertz V, et al. Survival of childhood polycystic kidney disease following renal transplantation: the impact of advanced hepatobiliary disease. Pediatr Transplant 2003;7:364-9.
6. Khan K, Schwarzenberg SJ, Sharp HL, et al. Morbidity from congenital hepatic fibrosis after renal transplantation for autosomal recessive polycystic kidney disease. Am J Tranplant 2002;2:360-5.
7. Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002;30:259-69.
8. Bataller R, Gabele E, Parsons CJ, et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005;41:1046-55.
9. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
10. Paizis G, Cooper ME, Schembri JM, et al. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002;123:1667-76.
11. Wells RG, Fibrogenesis V. TGF-beta signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000;279: G845-50.
12. Lager DJ, Qian Q, Bengal RJ, et al. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 2001;59:126-36.
13. Sanzen T, Harada K, Yasoshima M, et al. Polycystic kidney rat is a novel animal model of Caroli's disease associated with congenital hepatic fibrosis. Am J Pathol 2001;158:1605-12.
14. Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 30, 50-cyclic monophosphate. Gastroenterology 2007;132:1104-16.
15. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006;86:747-803.
16. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-94.
17. Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol 2007;22(Suppl 1): S93-5.
18. Ishizaka N, Saito K, Noiri E, et al. Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver. Am J Physiol Regul Integr Comp Physiol 2005;288: R1063-70.
19. Eyries M, Agrapart M, Alonso A, et al. Phorbol ester induction of angiotensin-converting enzyme transcription is mediated by Egr-1 and AP-1 in human endothelial cells via ERK1/2 pathway. Circ Res 2002;91:899-906.
20. Xavier-Neto J, Pereira AC, Junqueira ML, et al. Rat angiotensin- converting enzyme promoter regulation by beta-adrenergics and cAMP in endothelium. Hypertension 1999;34:31-8.
21. Xavier-Neto J, Pereira AC, Oliveira EM, et al. Control of the rat angiotensin I converting enzyme gene by CRE-like sequences. Braz J Med Biol Res 2004;37:1441-53.
22. Guyot C, Lepreux S, Combe C, et al. Hepatic fibrosis and cirrhosis: the (myo) fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006;38:135-51.